Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells

ConclusionProscillaridin A produces anticancer and epigenetic effects in the low nanomolar range and its combination with decitabine warrants further investigation for the treatment of eRMS.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research